MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

MediciNova Inc

Deschisă

SectorSănătate

1.48 0.68

Rezumat

Modificarea prețului

24h

Curent

Minim

1.43

Maxim

1.54

Indicatori cheie

By Trading Economics

Venit

38K

-2.8M

EPS

-0.06

Angajați

13

EBITDA

125K

-3.2M

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-14M

72M

Deschiderea anterioară

0.8

Închiderea anterioară

1.48

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

MediciNova Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 23:54 UTC

Acțiuni populare

Stocks to Watch: Alphabet, Intel, AppFolio

24 apr. 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 apr. 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 apr. 2025, 23:37 UTC

Top știri

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 apr. 2025, 23:36 UTC

Top știri

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 apr. 2025, 23:13 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 apr. 2025, 23:09 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 apr. 2025, 23:02 UTC

Achiziții, Fuziuni, Preluări

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 apr. 2025, 22:51 UTC

Top știri
Achiziții, Fuziuni, Preluări

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 apr. 2025, 22:48 UTC

Top știri

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 apr. 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 apr. 2025, 22:38 UTC

Market Talk
Câștiguri

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 apr. 2025, 22:24 UTC

Câștiguri

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 apr. 2025, 22:24 UTC

Market Talk
Câștiguri

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 apr. 2025, 22:23 UTC

Câștiguri

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

24 apr. 2025, 22:11 UTC

Market Talk
Câștiguri

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 apr. 2025, 22:09 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 apr. 2025, 22:00 UTC

Market Talk
Câștiguri

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 apr. 2025, 21:39 UTC

Top știri

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr. 2025, 21:24 UTC

Top știri
Câștiguri

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 apr. 2025, 21:23 UTC

Top știri
Câștiguri

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 apr. 2025, 21:04 UTC

Câștiguri

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 apr. 2025, 21:03 UTC

Câștiguri

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 apr. 2025, 21:02 UTC

Câștiguri

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparație

Modificare preț

MediciNova Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.45 / N/ASuport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.